HighCape Capital

Wellinks is a medical technology company that specializes in the design and development of medical devices aimed at improving respiratory health. Founded in 2014 and headquartered in Fairfield, Connecticut, the company offers innovative solutions, including Flyp, a handheld nebulizer specifically designed for patients with respiratory diseases. Wellinks operates within the health and wellness sector, focusing on enhancing the quality of care for individuals suffering from such conditions.

Cybrexa, Inc. develops DNA repair inhibitors for radio- and chemo-sensitizers in cancer therapeutics. The product consists of peptide-based technology that directly targets tumor microenvironment. Cybrexa, Inc. was formerly known as Cybrexa, Inc. The company was founded in 2016 and is based in New Haven, Connecticut.

Alphina Therapeutics is a biotechnology company that aims to leverage proprietary biomarkers and breakthrough insights for cancer patients. Its focus is on leveraging the synthetic lethal context of certain cancer patient subsets that have NAD Metabolic Deficiencies (NMD) through the development of companion diagnostics. Their goal is to develop best-in-class targeted therapies against the NAD pathway nodes in patients whose cancers exhibit hallmarks of NMD and rapidly translate these into the clinic.

Flyp Nebulizer, the medical device is reinvented by Weblinks for respiratory care around the people who need it most. It works at ultrasonic speed to create a fine aerosol of medication. Flyp Nebulizer works quickly to deliver treatment within 7-minute average.

Wellinks is a medical technology company that specializes in the design and development of medical devices aimed at improving respiratory health. Founded in 2014 and headquartered in Fairfield, Connecticut, the company offers innovative solutions, including Flyp, a handheld nebulizer specifically designed for patients with respiratory diseases. Wellinks operates within the health and wellness sector, focusing on enhancing the quality of care for individuals suffering from such conditions.

Cybrexa, Inc. develops DNA repair inhibitors for radio- and chemo-sensitizers in cancer therapeutics. The product consists of peptide-based technology that directly targets tumor microenvironment. Cybrexa, Inc. was formerly known as Cybrexa, Inc. The company was founded in 2016 and is based in New Haven, Connecticut.

Zipline Medical, Inc. specializes in the development and marketing of non-invasive skin closure solutions, specifically through its patented Zip Surgical Skin Closure product. This innovative technology addresses the need for rapid, easy-to-use skin closure in various medical fields, including electrophysiology, cardiology, orthopedics, dermatology, emergency medicine, plastic and reconstructive surgery, obstetrics and gynecology, and general surgery. The company's PRELOC™ technology platform is designed to provide uniform closure forces while reducing tension that can lead to scarring, aiming to combine the efficiency of staples with the aesthetic benefits of sutures. Founded in 2009 and based in Campbell, California, Zipline Medical operates as a subsidiary of Stryker Corporation, leveraging its location in Silicon Valley to draw on expertise in medical device research and development. The company's focus on enhancing surgical procedures through improved skin closure techniques positions it as a valuable player in the medical device industry.

Cheetah’s proprietary CHEETAH NICOM system is CE marked and FDA cleared. It is the only non-invasive cardiac output monitor with substantial equivalence to the Swan Ganz thermodilution system for U.S. regulatory purposes. The CHEETAH NICOM is now used by leading medical centers around the globe providing clinicians with invaluable clinical information in complicated scenarios. Cheetah Medical is committed to ongoing research and development and close cooperation with clinicians.

Cybrexa, Inc. develops DNA repair inhibitors for radio- and chemo-sensitizers in cancer therapeutics. The product consists of peptide-based technology that directly targets tumor microenvironment. Cybrexa, Inc. was formerly known as Cybrexa, Inc. The company was founded in 2016 and is based in New Haven, Connecticut.

Aziyo is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. From our proprietary tissue processing platforms, we have developed a portfolio of advanced regenerative medical products that are designed to be very similar to natural biological material.

Zipline Medical, Inc. specializes in the development and marketing of non-invasive skin closure solutions, specifically through its patented Zip Surgical Skin Closure product. This innovative technology addresses the need for rapid, easy-to-use skin closure in various medical fields, including electrophysiology, cardiology, orthopedics, dermatology, emergency medicine, plastic and reconstructive surgery, obstetrics and gynecology, and general surgery. The company's PRELOC™ technology platform is designed to provide uniform closure forces while reducing tension that can lead to scarring, aiming to combine the efficiency of staples with the aesthetic benefits of sutures. Founded in 2009 and based in Campbell, California, Zipline Medical operates as a subsidiary of Stryker Corporation, leveraging its location in Silicon Valley to draw on expertise in medical device research and development. The company's focus on enhancing surgical procedures through improved skin closure techniques positions it as a valuable player in the medical device industry.

Cheetah’s proprietary CHEETAH NICOM system is CE marked and FDA cleared. It is the only non-invasive cardiac output monitor with substantial equivalence to the Swan Ganz thermodilution system for U.S. regulatory purposes. The CHEETAH NICOM is now used by leading medical centers around the globe providing clinicians with invaluable clinical information in complicated scenarios. Cheetah Medical is committed to ongoing research and development and close cooperation with clinicians.